GoodRx lists Wegovy pill at $149 a month for two lowest doses

GoodRx said on January 5 that the newly approved Wegovy pill (oral semaglutide) is available through its platform at a cash price of $149 a month for the two lowest doses, at more than 70,000 pharmacies nationwide ^[1].

The $149 price covers the 1.5 mg and 4 mg doses and runs through April 15, 2026, according to GoodRx. After that date, the 4 mg dose will cost $199 a month. The 9 mg and 25 mg doses are priced at $299 a month ^[1]. GoodRx described the figures as the lowest discounted cash prices for the first oral GLP-1, a company claim, and said the price applies to eligible self-pay patients ^[1]. A separate report on the federal TrumpRx portal, which launched February 5 and links patients to manufacturers' websites, cited an initial price of $150 for FDA-approved oral GLP-1 receptor agonists ^[2].

GoodRx also said it will begin connecting users to prescribers. The company said consumers will soon be able to use GoodRx for Weight Loss, its telemedicine subscription, to meet with licensed healthcare providers, complete eligibility assessments and, when clinically appropriate, receive a prescription for the Wegovy pill or other FDA-approved GLP-1 treatments ^[1]. No date was given for that service ^[1].

"We're excited to help consumers access one of the most anticipated weight-loss treatments on the market," said Wendy Barnes, president and CEO of GoodRx ^[1].

The Wegovy pill, 25 mg oral semaglutide, is the only FDA-approved GLP-1 pill for weight loss and is also approved to reduce the risk of major adverse cardiovascular events ^[2]. GoodRx's announcement came about a month before TrumpRx went live. That site does not sell medications; it links patients to manufacturers' websites, and purchases must be paid in cash because insurance is not accepted ^[2]. Reported discounts there include lowering monthly costs from $1,000 to $350 for Ozempic and from $1,350 to $350 for Wegovy, and from $1,086 to $346 for Zepbound (tirzepatide) ^[2].

Orforglipron, an oral GLP-1 from Eli Lilly, was still under FDA review at the time of that report. Eli Lilly has submitted a new drug application after topline results from a Phase 3 trial showed weight loss was maintained after people switched from an injectable weight-loss medication to oral therapy. If approved, the lowest dose of orforglipron would start at $149 ^[2].

Why it matters for patients

The $149 price is a cash price, meaning it applies to eligible patients who pay without insurance ^[1]. GoodRx says the Wegovy pill at that price is available at more than 70,000 pharmacies ^[1].

Cost depends on the dose. The $149 price applies only to the 1.5 mg and 4 mg doses, and only through April 15, 2026, for the 4 mg; higher doses are listed at $299 a month ^[1]. A first month's price is therefore not necessarily the price that continues.

Cash-only purchasing is a point of debate. TrumpRx does not accept insurance, which conflicts with some manufacturer direct-to-consumer programs that do ^[2]. Experts have cautioned that Americans could end up paying more if they go through such a site, because most of the medications involved are already covered by insurance and some have cheaper generic versions available ^[2]. Health policy experts also noted that savings will not be realized immediately or at all, and that the full details of the pricing deals may never be known ^[2].

What is not yet known: whether insurers will cover the Wegovy pill, what Novo Nordisk's own cash price for the pill is, and how widely providers will prescribe the oral form instead of injections. None of that has been reported in these accounts.

What happens next

April 15, 2026: The $149 monthly price for the 4 mg dose is scheduled to end, and a $199 monthly cash price for that dose is set to apply. The $149 price for the 1.5 mg dose is not tied to that end date in the announcement ^[1].

No date has been disclosed for when GoodRx for Weight Loss will begin connecting users to prescribers ^[1].

Orforglipron: An FDA decision date has not been reported. If it is approved, the lowest dose would start at $149, according to a report on the pricing agreements ^[2].